Destiny Pharma plc (GB:DEST) has released an update.
Destiny Pharma plc, a clinical-stage biotech company, has announced the issuance of 200,000 new ordinary shares following a former director’s share options exercise. The new shares are expected to commence trading on the AIM market of the London Stock Exchange on May 30, 2024. Post-issuance, the total number of ordinary shares in circulation will be 95,511,863, which shareholders can use as a reference for disclosure requirements.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.
